Treatment of Inflammatory Bowel Disease with Biologics (eBook)

Adam S. Cheifetz, MD Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA Joseph D. Feuerstein, MD Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

1. Mechanism of Action and Pharmacokinetics of BiologicsAlan C. Moss2. Anti-tumor Necrosis Factor Agents in Ulcerative Colitis Kindra Clark-Snustad, Ives Hot, Scott Lee3. Anti-tumor Necrosis Factor Agents in Crohn’s DiseaseByron P. Vaughn4. Anti-TNF Therapy for Treatment of Extraintestinal Manifestations of Inflammatory Bowel Disease Sarah Flier5. Use of Biologics in the Postoperative Management of Crohn’s DiseaseBenjamin H. Click, Miguel Reguiero6. Biologics in Pregnancy and BreastfeedingJill K. J. Gaidos, Sunanda V. Kane7. Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel DiseaseParambir S. Dulai, Corey A. Siegel8. Therapeutic Drug Monitoring of Biologic AgentsFrank I. Scott, Mark T. Osterman9. Use of Biologics in Crohn’s Disease and Ulcerative Colitis Prior to Surgery and Perioperative RisksAfrin Kamal, Bret Lashner10. Cessation of Biologics – Can it be Done?Hang Hock Shim, Cynthia H. Seow11. Biologic Therapy in Pediatric Inflammatory Bowel Disease Sona Patel, Jennifer Strople12. Infectious Complications of BiologicsRenée M. Marchioni Beery, Joshua R. Korzenik13. Tumor Necrosis Factor-Alpha Inhibitors and Risks of MalignancyJulia Hughes, Millie D. Long14. Non-infectious and Non-malignant Complications of Biologics Raymond Cross15. Biosimilars in Inflammatory Bowel Disease 2017: State of the Science, State of the Art, State of the FinancesAsher Kornbluth16. Anti-Integrin Agents in IBD: Efficacy and Risk of ComplicationsJimmy K. Limdi, Francis A. Farraye17. Novel Agents in Inflammatory Bowel DiseaseFernando Velayos18. Quality, Safety, and Practical Considerations of Using Biologic TherapiesGil Melmed